Bristol Myers Squibb announces two trials demonstrating Sotyktu efficacy in both moderate-to-severe scalp psoriasis
Posted on September 29, 2024
Bristol Myers Squibb has recently announced their new positive results from the Phase 3b/4 PSORIATYK SCALP trial evaluating Sotyktu for the treatment of patients with moderate-to-severe scalp psoriasis, including those with less extensive overall psoriasis. The primary endpoint was met, with a statistically significant improvement in the scalp-specific Physician’s Global Assessment response of 0 or 1 at 16 weeks, with more than three times as many patients achieving ss-PGA 0/1 with Sotyktu treatment compared to those on placebo.
“Approximately 80% of people living with plaque psoriasis have scalp involvement and typically experience itching, flaking, pain and bleeding, which greatly diminish their quality of life,” said Mark Lebwohl, MD, dean of Clinical Therapeutics at the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai and an investigator and paid consultant for Bristol Myers Squibb. “These new results reinforce that oral Sotyktu is a safe and effective once-daily treatment for people living with moderate-to-severe psoriasis, with involvement of high impact areas such as the scalp.”
This safety profile of Sotyktu in PSORIATYK SCALP was consistent with findings in previously conducted clinical trials of Sotyktu in psoriasis. The most common adverse events associated with Sotyktu treatment in the PSORIATYK SCALP trial were nasopharyngitis, upper respiratory tract infection, acne, headache, COVID-19 and pustular acne.
Related Topics and Keywords
BMS, Moderate-to-Severe Scalp Psoriasis, psoriasis, Sotyktu (deucravacitinib)
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy